Rentschler Biopharma further expands services in Japan and South Korea

Germany-based Rentschler Biopharma SE, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, is highlighting its flexible and optimised solutions for the development and manufacture of a wide range of biologics for clients in Japan and South Korea. 

As part of its ongoing commitment and strategic focus on further expanding its services in the region, Rentschler Biopharma will attend BioProcess International Asia in Kyoto. The company will also engage with long-standing and prospective partners to explore joint opportunities and understand evolving needs. 

With their well-established and growing biopharma industries, Japan and South Korea are key markets for biopharmaceutical development. Rentschler Biopharma has been active in the region for many years, serving a wide range of clients, with support from its established regional partner, Summit Pharmaceuticals International (SPI). 

During a roadshow in Japan, Rentschler Biopharma will provide an outlook on how the company is positioned to offer new and accelerated manufacturing capabilities, leveraging its deep understanding of the entire development and manufacturing spectrum for drug substance. The company has extensive expertise, specialized knowledge, and cutting-edge technology, providing comprehensive client support from the Rentschler Expression Platform for cell line development, upstream and downstream development, and GMP manufacturing to analytical testing, product characterisation, and regulatory affairs. 

To tailor its process development and manufacturing services to Japanese clients, Rentschler Biopharma is collaborating closely with SPI as its established partner, ensuring that clients benefit from seamless communication, localized regulatory insights, and culturally attuned project management.